Apoorv Kalra, MD
Infectious Disease · Overland Park, KSNPI 1740497122
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,430 of the $3,431 with a category attached, or 70.8%. Paratek Pharmaceuticals, Inc. accounts for 98.7% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2020 at $3,384 and has fallen 99.0% since, to $34 in 2025.
Across 11 payments — averaging $311.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Paratek Pharmaceuticals, Inc.$3K
- Insmed, Inc.$34
- Melinta Therapeutics, LLC$12
What the payments were for
- Consulting fees$2,43071%
- Travel & lodging$81124%
- Food & beverage$1665%
- Education$241%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Paratek Pharmaceuticals, Inc. | 8 | $3,384 |
| Insmed, Inc. | 2 | $34 |
| Melinta Therapeutics, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUZYRA$3,241
How this compares
$3,431 in reported general payments places this provider in the 85th percentile of 56 infectious disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 20 | $88,271 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 21 | $76,371 |
| ErtapenemErtapenem Sodium | 49 | $20,730 |
| Caspofungin Acetate | 23 | $17,132 |
| Daptomycin | 42 | $15,296 |
| Cefepime Hcl | 25 | $10,173 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 32 | $6,193 |
| Vancomycin Hcl | 35 | $5,854 |
| Itraconazole | 19 | $5,382 |
| Atovaquone | 11 | $4,540 |
| Cefdinir | 49 | $4,336 |
| CeftriaxoneCeftriaxone Sodium | 64 | $2,625 |
| MicafunginMicafungin Sodium | 12 | $2,623 |
| Meropenem | 13 | $2,353 |
| Doxycycline Hyclate | 81 | $2,226 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Overland Park
- John FriedOverland Park$7K
- Jared FrisbyOverland Park$281
- Michael DriksOverland Park$225
- Himal BajracharyaOverland Park$12
- Thomas MooreWichita$37K
- Wissam El AtrouniKansas City$15K
- Maha AssiWichita$9K
- Marjorie WongskhaluangLeawood$5K
- Margaret HaganWichita$4K
- Samir DesaiShawnee$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.